GALLIUM (GA67) CITRATE INJECTION DIN 02327813
Health Canada record
| Active ingredient(s) | GALLIUM CITRATE GA 67 74 MBq |
|---|---|
| Dosage form | Solution |
| Route | Intravenous |
| Schedule | SCHEDULE C |
| Class | Radiopharmaceutical |
| ATC | V09HX01 GALLIUM 67 GA CITRATE |
| Original market date | 22-Jul-2019 |
| Current status date | 22-Jul-2019 |
| Source | Health Canada DPD |
Establishment licence of the holder
Curium Canada Inc. — licence 3-002566, currently licensed, last inspection rating C (2026-07-20).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing GALLIUM CITRATE GA
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02327759 | GALLIUM | LANTHEUS MI CANADA INC | Solution | GALLIUM CITRATE GA 67 74 MBq | Cancelled Post Market |
| 02329816 | GALLIUM CITRATE GA 67 INJECTION | BRISTOL-MYERS SQUIBB CANADA | Solution | GALLIUM CITRATE GA 67 2 MCI | Cancelled Pre Market |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 22092 | 2019-04-26 | New Drug Submission (NDS) | MANUFACTURER NAME CHANGE |
International API supply for GALLIUM CITRATE GA
0 active FDA Drug Master Files.
Request a quote for GALLIUM (GA67) CITRATE INJECTION